Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

Orgenesis logo
$1.33 -0.20 (-13.07%)
As of 12:46 PM Eastern

About Orgenesis Stock (NASDAQ:ORGS)

Key Stats

Today's Range
$1.28
$1.49
50-Day Range
$1.48
$2.48
52-Week Range
$0.87
$10.80
Volume
12,038 shs
Average Volume
8,399 shs
Market Capitalization
$6.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orgenesis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

ORGS MarketRank™: 

Orgenesis scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Orgenesis.

  • Percentage of Shares Shorted

    0.13% of the float of Orgenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Orgenesis has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Orgenesis has recently decreased by 12.86%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Orgenesis does not currently pay a dividend.

  • Dividend Growth

    Orgenesis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Orgenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Orgenesis has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Orgenesis has recently decreased by 12.86%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    Only 1 people have added Orgenesis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Orgenesis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.66% of the stock of Orgenesis is held by insiders.

  • Percentage Held by Institutions

    Only 22.56% of the stock of Orgenesis is held by institutions.

  • Read more about Orgenesis' insider trading history.
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Stock News Headlines

Orgenesis Delays Filing of Quarterly Report
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
See More Headlines

ORGS Stock Analysis - Frequently Asked Questions

Orgenesis' stock was trading at $1.89 at the beginning of the year. Since then, ORGS stock has decreased by 29.6% and is now trading at $1.33.

Orgenesis Inc. (NASDAQ:ORGS) posted its earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The company had revenue of $6.98 million for the quarter.

Shares of Orgenesis reverse split on the morning of Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orgenesis subsidiaries include Koligo Therapeutics, and Tamir Biotechnology Inc.

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

Last Earnings
8/11/2023
Today
7/03/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
150
Year Founded
2008

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.36 million
Net Margins
-3,827.81%
Pretax Margin
-3,931.93%

Debt

Sales & Book Value

Annual Sales
$662 thousand
Price / Cash Flow
N/A
Book Value
($6.58) per share
Price / Book
-0.22

Miscellaneous

Free Float
4,527,000
Market Cap
$7.10 million
Optionable
No Data
Beta
0.54

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ORGS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners